Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
34
RCUS Quote, Financials, Valuation and Earnings
Last price:
$15.81
Seasonality move
:
-4%
Day range:
$15.46 - $16.00
52-week range:
$13.52 - $20.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.20x
P/B ratio:
2.58x
Volume:
157.2K
Avg. volume:
686.2K
1-year change:
-12.34%
Market cap:
$1.5B
Revenue:
$117M
EPS (TTM):
-$3.15
Analysts' Opinion
-
Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.13, Arcus Biosciences has an estimated upside of 108.67% from its current price of $15.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 100% downside risk from its current price of $15.91.
Fair Value
-
According to the consensus of 9 analysts, Arcus Biosciences has 108.67% upside to fair value with a price target of $33.13 per share.
RCUS vs. S&P 500
-
Over the past 5 trading days, Arcus Biosciences has underperformed the S&P 500 by -3.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arcus Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arcus Biosciences has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Arcus Biosciences reported revenues of $48M.
Earnings Growth
-
Arcus Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arcus Biosciences reported earnings per share of -$1.00.
Enterprise value:
413.9M
EV / Invested capital:
0.68x
Price / LTM sales:
5.20x
EV / EBIT:
--
EV / Revenue:
1.57x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-22.44%
Net Income Margin (TTM):
-102.66%
Return On Equity:
-46.73%
Return On Invested Capital:
-45.98%
Operating Margin:
-218.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $432.6M | $120M | $263M | $32M | $48M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $75M | -$323M | -$298M | -$80M | -$105M | |
| EBITDA | $90M | -$279M | -$257M | -$67M | -$89M | |
| Diluted EPS | $0.92 | -$4.00 | -$3.15 | -$0.94 | -$1.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $797.2M | $545.3M | $1.1B | $882M | $1.1B | |
| Total Assets | $811.1M | $839.3M | $1.4B | $1.2B | $1.3B | |
| Current Liabilities | $162.9M | $142.9M | $177.2M | $200M | $215M | |
| Total Liabilities | $266.7M | $296.7M | $695.1M | $671M | $687M | |
| Total Equity | $544.4M | $542.6M | $698.7M | $520M | $565M | |
| Total Debt | -- | -- | -- | -- | $47M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $446.1M | -$288M | -$158M | -$63M | $26M | |
| Cash From Investing | -$441.2M | $213M | -$107M | $11M | -$29M | |
| Cash From Financing | $33.3M | $41M | $282M | $6M | $48M | |
| Free Cash Flow | $425.6M | -$306M | -$169M | -$73M | $25M | |
RCUS
Sector
Market Cap
$1.5B
$46.1M
Price % of 52-Week High
78.34%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-16.97%
-0.6%
1-Year Price Total Return
-12.34%
-30.52%
Beta (5-Year)
0.877
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$15.83
200-day SMA
Sell
Level
$16.21
Bollinger Bands (100)
Sell
Level
15.19 - 17.43
Chaikin Money Flow
Sell
Level
-7.4M
20-day SMA
Sell
Level
$16.38
Relative Strength Index (RSI14)
Sell
Level
47.65
ADX Line
Sell
Level
9.17
Williams %R
Neutral
Level
-65.7617
50-day SMA
Sell
Level
$16.31
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
4.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.1962)
Sell
CA Score
(Annual)
Level (-1.7231)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.6544)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Stock Forecast FAQ
In the current month, RCUS has received 7 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RCUS average analyst price target in the past 3 months is $33.13.
-
Where Will Arcus Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arcus Biosciences share price will rise to $33.13 per share over the next 12 months.
-
What Do Analysts Say About Arcus Biosciences?
Analysts are divided on their view about Arcus Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcus Biosciences is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Arcus Biosciences's Price Target?
The price target for Arcus Biosciences over the next 1-year time period is forecast to be $33.13 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RCUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arcus Biosciences is a Buy. 7 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RCUS?
You can purchase shares of Arcus Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcus Biosciences shares.
-
What Is The Arcus Biosciences Share Price Today?
Arcus Biosciences was last trading at $15.81 per share. This represents the most recent stock quote for Arcus Biosciences. Yesterday, Arcus Biosciences closed at $15.91 per share.
-
How To Buy Arcus Biosciences Stock Online?
In order to purchase Arcus Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
